Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation

The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant...

Full description

Saved in:
Bibliographic Details
Published inInfekt͡s︡ii͡a︡ i immunitet Vol. 14; no. 1; pp. 35 - 45
Main Authors Afridonova, Z. E., Toptygina, A. P., Semikina, E. L.
Format Journal Article
LanguageEnglish
Published 28.04.2024
Online AccessGet full text

Cover

Loading…
Abstract The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant SARS-CoV-2 strains. The aim was to study humoral and cellular immunity in a group of COVID-19 convalescent subjects within 3 years after the primary infection. The longitudinal study included 38 adults aged 23–72 years with PCR-confirmed mild or moderate COVID-19 in the second half of 2020. Within three-year follow-up after the onset, the subjects were examined every 6 months for the level of humoral and cellular immunity against SARS-CoV-2 antigens. The parameters of humoral immunity were assessed by enzyme immunoassay using “SARS-CoV-2-IgG quantitative-ELISA-BEST” kits (Vector-Best JSC, Novosibirsk, Russian Federation) for S-protein and “N-CoV-2-IgG PS” (Saint-Petersburg Pasteur Institute, St. Petersburg, Russian Federation) specific to the N-protein. Cellular anti-SARS-CoV-2 immunity was analyzed by evaluating surface CD107a expression on CD8high lymphocytes stimulated with the SARS-CoV-2 S- or N-antigens. It was shown that the dynamics of antibody levels against SARS-COV-2 antigens depends on antigen (S- or N-protein) type, antibody class (IgG or IgA) as well as individual contact history with new SARS-CoV-2 strains. The dynamics of cytotoxic CD8highCD107a+ lymphocyte percentage is moderately positively correlated with that of the corresponding anti-S or N antibody levels. At the same time, change in the levels of both humoral and T-cell responses to SARS-CoV-2 S- or N-protein antigens are weakly negatively correlated with each other. A strong positive correlation was found between changes in the anti-S IgG antibody level and avidity. Avoiding the anti-S IgG neutralization due to frequent mutations of new SARS-CoV-2 strains leads to induced new primary immune responses against SARS-CoV-2 antigens along with the activation of existing responses formed to previous coronavirus strains. The study of immune responses against SARS-CoV-2 antigens allows to predict the persistence of high SARS-CoV-2 anti-S antibody and T-cell response levels.
AbstractList The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to understand for how long post-infectious and post-vaccination immunity may last and how effectively established immunity could act against new mutant SARS-CoV-2 strains. The aim was to study humoral and cellular immunity in a group of COVID-19 convalescent subjects within 3 years after the primary infection. The longitudinal study included 38 adults aged 23–72 years with PCR-confirmed mild or moderate COVID-19 in the second half of 2020. Within three-year follow-up after the onset, the subjects were examined every 6 months for the level of humoral and cellular immunity against SARS-CoV-2 antigens. The parameters of humoral immunity were assessed by enzyme immunoassay using “SARS-CoV-2-IgG quantitative-ELISA-BEST” kits (Vector-Best JSC, Novosibirsk, Russian Federation) for S-protein and “N-CoV-2-IgG PS” (Saint-Petersburg Pasteur Institute, St. Petersburg, Russian Federation) specific to the N-protein. Cellular anti-SARS-CoV-2 immunity was analyzed by evaluating surface CD107a expression on CD8high lymphocytes stimulated with the SARS-CoV-2 S- or N-antigens. It was shown that the dynamics of antibody levels against SARS-COV-2 antigens depends on antigen (S- or N-protein) type, antibody class (IgG or IgA) as well as individual contact history with new SARS-CoV-2 strains. The dynamics of cytotoxic CD8highCD107a+ lymphocyte percentage is moderately positively correlated with that of the corresponding anti-S or N antibody levels. At the same time, change in the levels of both humoral and T-cell responses to SARS-CoV-2 S- or N-protein antigens are weakly negatively correlated with each other. A strong positive correlation was found between changes in the anti-S IgG antibody level and avidity. Avoiding the anti-S IgG neutralization due to frequent mutations of new SARS-CoV-2 strains leads to induced new primary immune responses against SARS-CoV-2 antigens along with the activation of existing responses formed to previous coronavirus strains. The study of immune responses against SARS-CoV-2 antigens allows to predict the persistence of high SARS-CoV-2 anti-S antibody and T-cell response levels.
Author Afridonova, Z. E.
Toptygina, A. P.
Semikina, E. L.
Author_xml – sequence: 1
  givenname: Z. E.
  surname: Afridonova
  fullname: Afridonova, Z. E.
– sequence: 2
  givenname: A. P.
  surname: Toptygina
  fullname: Toptygina, A. P.
– sequence: 3
  givenname: E. L.
  surname: Semikina
  fullname: Semikina, E. L.
BookMark eNo1kMtOwzAURC1UJErpH7DwD7jY10kcL6uKR6UiBClsLSe5LkGNjewUqX_fB7CaWYxGOueajHzwSMit4DORq1LfAQBnqhCaVctnJlSuiwsyBikkU1KXo2P_X1yRaUpfnHOhALQsxuS12qXBdh5b2vX9zodt2HSN3dIe-xD3dAi0mr9VbBE-GFDrh26DPs3o-jMi0j3amGhwNNQJ448duuBvyKWz24TTv5yQ94f79eKJrV4el4v5ijVCFQOTDtBCawsoS2hRNa5EIZWrwTWgM1e3WqvC5bkGbmt3BBUZb7FUbaZ5rYWckOz3t4khpYjOfMeut3FvBDdnM-bEbU7c5mjGnM3IA3LIWO4
Cites_doi 10.3390/v14050941
10.1016/S2666-7568(21)00282-8
10.1016/S0140-6736(21)01642-1
10.1038/s41586-020-2548-6
10.1038/s41590-020-00814-z
10.4049/jimmunol.174.8.4718
10.15789/2220-7619-AOF-2107
10.1134/S0006297924050080
10.1001/jama.2022.1393
10.1038/s41598-021-95045-z
10.1016/j.immuni.2020.07.005
10.4049/jimmunol.2100135
10.1126/sciimmunol.abd7114
10.3233/HAB-210440
10.15789/2220-7619-CAN-1904
10.3389/fimmu.2021.647934
10.3389/fimmu.2023.1133225
10.1038/s41467-021-27674-x
10.3390/vaccines10071143
10.1038/s41586-021-03696-9
10.1056/NEJMoa2109072
10.1172/JCI142004
10.1038/s41467-023-36250-4
10.1126/sciimmunol.ade2798
10.1128/jvi.00760-22
10.1016/j.chom.2020.09.002
10.1126/sciimmunol.abg6916
10.15789/2220-7619-COT-1809
10.1126/sciimmunol.abj1750
10.1038/s41591-021-01377-8
10.15789/2220-7619-MIM-2009
10.3390/biom13091338
10.1016/j.ejim.2021.09.012
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.15789/2220-7619-SIM-17596
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2313-7398
EndPage 45
ExternalDocumentID 10_15789_2220_7619_SIM_17596
GroupedDBID 642
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
GROUPED_DOAJ
KQ8
ID FETCH-LOGICAL-c176t-3f2ea2da62882de7cf8e137fb2fc294fbd9976f55920abf789140de87d490b913
ISSN 2220-7619
IngestDate Tue Jul 01 00:41:21 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c176t-3f2ea2da62882de7cf8e137fb2fc294fbd9976f55920abf789140de87d490b913
OpenAccessLink https://iimmun.ru/iimm/article/download/17596/1939
PageCount 11
ParticipantIDs crossref_primary_10_15789_2220_7619_SIM_17596
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-04-28
PublicationDateYYYYMMDD 2024-04-28
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-28
  day: 28
PublicationDecade 2020
PublicationTitle Infekt͡s︡ii͡a︡ i immunitet
PublicationYear 2024
References ref13
ref12
ref15
ref14
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref14
  doi: 10.3390/v14050941
– ident: ref15
  doi: 10.1016/S2666-7568(21)00282-8
– ident: ref30
  doi: 10.1016/S0140-6736(21)01642-1
– ident: ref33
  doi: 10.1038/s41586-020-2548-6
– ident: ref32
  doi: 10.1038/s41590-020-00814-z
– ident: ref29
  doi: 10.4049/jimmunol.174.8.4718
– ident: ref3
  doi: 10.15789/2220-7619-AOF-2107
– ident: ref1
  doi: 10.1134/S0006297924050080
– ident: ref6
  doi: 10.1001/jama.2022.1393
– ident: ref19
  doi: 10.1038/s41598-021-95045-z
– ident: ref28
  doi: 10.1016/j.immuni.2020.07.005
– ident: ref10
  doi: 10.4049/jimmunol.2100135
– ident: ref17
  doi: 10.1126/sciimmunol.abd7114
– ident: ref25
  doi: 10.3233/HAB-210440
– ident: ref2
  doi: 10.15789/2220-7619-CAN-1904
– ident: ref21
  doi: 10.3389/fimmu.2021.647934
– ident: ref22
  doi: 10.3389/fimmu.2023.1133225
– ident: ref16
  doi: 10.1038/s41467-021-27674-x
– ident: ref18
  doi: 10.3390/vaccines10071143
– ident: ref31
  doi: 10.1038/s41586-021-03696-9
– ident: ref7
  doi: 10.1056/NEJMoa2109072
– ident: ref13
  doi: 10.1172/JCI142004
– ident: ref24
  doi: 10.1038/s41467-023-36250-4
– ident: ref11
  doi: 10.1126/sciimmunol.ade2798
– ident: ref23
  doi: 10.1128/jvi.00760-22
– ident: ref20
  doi: 10.1016/j.chom.2020.09.002
– ident: ref27
  doi: 10.1126/sciimmunol.abg6916
– ident: ref5
  doi: 10.15789/2220-7619-COT-1809
– ident: ref9
  doi: 10.1126/sciimmunol.abj1750
– ident: ref12
  doi: 10.1038/s41591-021-01377-8
– ident: ref4
  doi: 10.15789/2220-7619-MIM-2009
– ident: ref26
  doi: 10.3390/biom13091338
– ident: ref8
  doi: 10.1016/j.ejim.2021.09.012
SSID ssj0001722936
ssib046627272
ssib044739665
Score 2.2544737
Snippet The COVID-19 pandemic has ended, but SARS-CoV-2 continues to actively circulate and mutate in the human population. In this regard, it is important to...
SourceID crossref
SourceType Index Database
StartPage 35
Title Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEBIvaHyJMYb8QJ8ih8bO4vixK502xBCQDu0tshNbiqY105Y9lD-Dv5iznbmBVYjxEkWX5pzkfjrfXe8DoXeZkVxKs0-kqGqSKs2JyitKpMplpZjJjbEFziefs6PT9OPZ_tlo9HOQtXTTqbj6sbGu5H-kCjSQq62SvYdkA1MgwDnIF44gYTj-k4wLX_0ENmNjyzyCHruw6bPOrCym3woya78TGsEntJ03r-NoAfLT0Qow7vI4WhUis0NT9Xhp9Hk3nn0YT5Pr8fxwfJDDWdN4igyUqPGrg-0aUmjs9KG6tfNW3Z8fcTSP1-Hsy25lh0E4rRRHX8KVQl805_2FeRx9iocRCeoSWehAiYLJMSE2POL3GE9jCSOc-YnTQfOmdxDm1ajvYNJvyL7d5B1VD6rGtkoNi5Hi-ISAMSQ2dNb-Y8cLeYjWA7J8SsultFxK4FI6Lg_QQwquBx246aCj0hReYtAiMLUN9Glfe-zienCLcJMpw5P1FZt2ofcbHndgEQ1Mm8U2etL7JHjqAfYUjfTyGXrkp5SunqOvAWb4N5hhDzPctXgNMxxghh3MsIMZbg0ewOwFOj2cL2ZHpJ_EQaqEZx1hhmpJa2lnU9Na88rkOmHcKGoqKlKjagFmrQHvlE6kMvCi4LfXOud1KiZKJOwl2lq2S_0KYaYFn-iamUSYNKsyuDWXlFZcMiqZMTuI3H6N8tI3XCn_JqbX9_z9Lnq8xuwbtNVd3eg9sCs79dYJ-hecOWwr
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+immunological+memory+to+SARS-CoV-2+antigens.+Three+years+of+observation&rft.jtitle=Infekt%CD%A1s%EF%B8%A1ii%CD%A1a%EF%B8%A1+i+immunitet&rft.au=Afridonova%2C+Z.+E.&rft.au=Toptygina%2C+A.+P.&rft.au=Semikina%2C+E.+L.&rft.date=2024-04-28&rft.issn=2220-7619&rft.eissn=2313-7398&rft.volume=14&rft.issue=1&rft.spage=35&rft.epage=45&rft_id=info:doi/10.15789%2F2220-7619-SIM-17596&rft.externalDBID=n%2Fa&rft.externalDocID=10_15789_2220_7619_SIM_17596
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2220-7619&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2220-7619&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2220-7619&client=summon